Ipsen is increasing its investment in the UK as a key market, despite continued qualms around the region's relationship with Europe and access to the single market, said Ewan McDowall, Ipsen UK and Ireland's vice-president of commercial operations.
The French specialty biopharma is also celebrating the introduction of its kidney cancer therapy Cabometyx (cabozantinib) onto the National Health Service in England and Wales – a drug around 300...